Interaction between gut microbiota and immune checkpoint inhibitor-related colitis
Immune checkpoint inhibitors (ICIs) have become a promising therapeutic strategy for malignant tumors, improving patient prognosis, along with a spectrum of immune-related adverse events (irAEs), including gastrointestinal toxicity, ICI-related colitis (IRC), and diarrhea. The gut microbiota has bee...
Main Authors: | Guanzhou Zhou, Nana Zhang, Ke Meng, Fei Pan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1001623/full |
Similar Items
-
Checkpoint Inhibitor-Induced Colitis: An Update
by: Giuseppe Losurdo, et al.
Published: (2023-05-01) -
Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management
by: Maria Terrin, et al.
Published: (2023-07-01) -
Gut microbiome in modulating immune checkpoint inhibitors
by: Xiang Li, et al.
Published: (2022-08-01) -
Capsulized Fecal Microbiota Transplantation Induces Remission in Patients with Ulcerative Colitis by Gut Microbial Colonization and Metabolite Regulation
by: Qiongyun Chen, et al.
Published: (2023-06-01) -
Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review
by: Sung Wook Hwang, et al.
Published: (2023-10-01)